O. Fitoussi

发表

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

L. Vercellino, P. Gaulard, G. Salles, 2020 .

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

J. Cerhan, G. Salles, D. Maucort-Boulch, 2018, Blood.

Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study

S. Leprêtre, A. Delmer, S. Choquet, 2017, Leukemia & lymphoma.

A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients

C. Fermé, C. Soussain, D. Decaudin, 2008, Anti-cancer drugs.

Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3).

B. Coiffier, O. Casasnovas, P. Feugier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of relapsed or refractory follicular lymphoma patients in daily practice – a French non-interventional study

G. Salles, P. Feugier, C. Haioun, 2018, Leukemia & lymphoma.

Advanced paraganglioma: A role for chemotherapy?

B. Bui, J. Coindre, M. Debled, 1999 .

Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins’s disease or non-Hodgkin’s lymphoma

C. Gisselbrecht, C. Fermé, C. Hennequin, 1999, Bone Marrow Transplantation.

Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study

G. Salles, R. Bouabdallah, A. Delmer, 2016, American journal of hematology.

Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Jesús Martín Sánchez, M. Beksac, H. Goldschmidt, 2018, Clinical lymphoma, myeloma & leukemia.

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.

B. Coiffier, C. Haioun, J. Gabarre, 2013, European journal of cancer.

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies

F. Jardin, P. Gaulard, H. Tilly, 2018, Cancer medicine.

Impact of rituximab on stem cell mobilization following ACVBP regimen in poor‐risk patients with diffuse large B‐cell lymphoma: results from a large cohort of patients

G. Salles, H. Tilly, N. Mounier, 2013, Transfusion.

Blastoid and common variants of mantle cell lymphoma exhibit distinct immunophenotypic and interphase FISH features

P. Dubus, G. Marit, J. Merlio, 2006, Histopathology.

Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts).

G. Salles, O. Casasnovas, H. Tilly, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study

E. Wattel, C. Rose, O. Beyne-Rauzy, 2016 .

Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy

J. Cerhan, G. Salles, D. Maucort-Boulch, 2017 .

Splitting bone marrow trephines into frozen and fixed fragments allows parallel histological and molecular detection of B cell malignant infiltrates

P. Dubus, J. Merlio, O. Fitoussi, 2006, Journal of Clinical Pathology.

Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study

G. Salles, O. Casasnovas, H. Tilly, 2011, Haematologica.

Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study

A. Fourrier-Réglat, N. Moore, E. Bignon, 2014, Leukemia & lymphoma.

EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia

G. Marit, N. Milpied, R. Tabrizi, 2007, Leukemia.

Sequential Development of Hodgkin's Disease and CD30+ Diffuse Large B-Cell Lymphoma in a Patient With MALT-Type Lymphoma: Evidence of Different Clonal Origin of Single Microdissected Reed-Sternberg Cells

P. Dubus, J. Merlio, G. Marit, 2002, The American journal of surgical pathology.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

B. Pégourié, O. Decaux, M. Mohty, 2016, Blood.

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

O. Decaux, P. Moreau, H. Avet-Loiseau, 2021, Leukemia.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

O. Decaux, A. Duhamel, P. Moreau, 2019, Clinical Cancer Research.

The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma

P. Moreau, H. Avet-Loiseau, X. Leleu, 2013, Clinical Cancer Research.

Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment

F. Durrieu, F. Lacombe, J. Reiffers, 2000, Leukemia.

Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma.

G. Marit, O. Fitoussi, L. Cany, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

F. Jardin, P. Gaulard, B. Coiffier, 2011, The Lancet. Oncology.

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Catherine Thieblemont, Nicolas Mounier, Richard Delarue, 2013, The Lancet. Oncology.

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

J. Cerhan, G. Salles, T. Habermann, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

G. Salles, O. Casasnovas, P. Feugier, 2011, Haematologica.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study

S. Leprêtre, A. Delmer, S. Choquet, 2019, Leukemia & lymphoma.

High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP.

L. Vercellino, P. Gaulard, G. Salles, 2020, Blood.

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

T. Molina, O. Casasnovas, P. Feugier, 2022, Blood advances.

A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort

G. Salles, C. Haioun, L. Fornecker, 2021, BMC Public Health.

Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study

M. Béné, V. Ugo, E. Lippert, 2018, American journal of hematology.

FCGR3A/2A polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts

J. Cerhan, T. Molina, G. Salles, 2017, Hematological oncology.

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs

O. Decaux, A. Lamblin, P. Moreau, 2013, Thrombosis and Haemostasis.

A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients

P. Cony-Makhoul, J. Reiffers, G. Marit, 2001, Bone Marrow Transplantation.

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

R. Greil, P. Gaulard, B. Coiffier, 2019, British journal of haematology.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

J. Cerhan, T. Molina, G. Salles, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort

J. Benichou, A. Fourrier-Réglat, N. Moore, 2016, Leukemia & lymphoma.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

B. Pégourié, P. Cony-Makhoul, O. Decaux, 2015, Haematologica.

Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study

B. Coiffier, O. Casasnovas, P. Feugier, 2008 .

Treatment emergent peripheral neuropathy in the CASSIOPEIA trial

P. Sonneveld, B. van der Holt, M. Delforge, 2022, Haematologica.

MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte

C. Copie-Bergman, M. Baia, T. Molina, 2012 .

Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B)

F. Jardin, B. Coiffier, H. Tilly, 2014 .

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

F. Jardin, B. Coiffier, H. Tilly, 2017, The Lancet. Haematology.

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

K. Tarte, R. Houot, L. Xerri, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy

H. Wallerand, O. Fitoussi, J. Riviere, 2023, Urologia Internationalis.

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

P. Moreau, G. Marit, G. Damaj, 2012, Leukemia & lymphoma.

Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial

B. Pégourié, O. Decaux, P. Moreau, 2012 .

A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial.

P. Gaulard, B. Coiffier, F. Morschhauser, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol.

B. Pégourié, O. Decaux, P. Moreau, 2012 .

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

J. Cerhan, T. Molina, G. Salles, 2017 .

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

O. Decaux, P. Moreau, X. Leleu, 2015 .

Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study.

B. Coiffier, O. Casasnovas, H. Tilly, 2006 .

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

A. Rosenwald, M. Ziepert, T. Molina, 2023, Blood advances.

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era